Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Soluble CD4 effectively prevents excessive TLR activation of resident macrophages in the onset of sepsis

Fig. 3

sCD4 protein effectively dampened TLRs inflammation. a ELISA measurement serum sCD4 after mice (n = 10) received LPS for the indicated time. TNF/IL-6 production 16 h after LPS stimulation of BMDM pre-incubated with 50 nM of (b) sCD4, (c) different ectodomains of sCD4, or (d) sCD4 but LPS was replaced with agonists for polyI:C (100 μg/mL), CpG-ODN (0.03 μM) or VSV (MOI = 5). e Survival rates and (f) serum TNF and IL-6 levels at the indicated time after WT mice were injected with sCD4 (10 mg/kg) (n = 10) or PBS (n = 11), 12 h before LPS challenge. g–i Changes of body weights after hACE2 mice pre-treated with sCD4 were infected with SARS-CoV-2 for 4 days (g). h TNF and IL-6 mRNA in lung by qPCR and (i) representative sections and pathology score of the lobe of left lung (with respective magnifications of areas of interest) on day 4. Mean ± SD are shown; n = 3–5 mice used where indicated; Statistics (ns, p > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001): Log-rank (Mantel-Cox) test (e), Unpaired t test (d, f, g–i), one-way ANOVA with Dunnett’s analysis (b, c)

Back to article page